Trials
2 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo”In the company’s words, NCT07161843 on ClinicalTrials.gov
- Tested for
- Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure, Acute Renal Failure (ARF), Acute Tubular Necrosis
- Main trialPhase 2/3
- “Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.”In the company’s words, NCT06866236 on ClinicalTrials.gov
- Other names
- Eseronate
Other drugs for Chronic Kidney Diseases
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
- Migalastat HClAmicus Therapeutics · Phase 3
- VicadrostatBoehringer Ingelheim · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
Coming up1
- 30 DecPhase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | Oct 2026 | Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression | |
| Phase 2/3Not yet recruiting | 30 Dec 2026 | Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) | |
| Phase 2Completed | 30 Aug 2024 | Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026